TONMYA’s launch is rapidly inflecting into what could become one of the most overlooked commercial ramps in small-cap biotech. For the week ended March 20, 2026, Symphony reported 572 TRx / 465 NRx and $935K in weekly gross sales, a sharp +23.8% WoW increase from $755K the prior week. Importantly, as previously validated in prior company reporting, Symphony does not capture 100% of channel sales, making the company’s established 1.5x adjustment highly relevant—implying true weekly gross sales of \~$1.40M, or an annualized run rate approaching $73M. With UnitedHealthcare reimbursement now entering the mix in April, the next leg of growth could be materially stronger as access expands and refill momentum compounds. If this trajectory continues, TONMYA could cross the company’s \~$2M weekly cash burn threshold as early as late April, potentially making cash-flow positivity visible by late April to early May. The market may be dramatically underestimating how quickly TNXP can rerate. This is not a finantial advice, make your own DD.